866-997-4948(US-Canada Toll Free)

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 107 Pages

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016, provides in depth analysis on Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted pipeline therapeutics.

The report provides comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
- The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
- The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) Overview 9
Therapeutics Development 10
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Stage of Development 10
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Therapy Area 11
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Indication 12
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Companies 17
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Products under Development by Universities/Institutes 21
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment 23
Assessment by Monotherapy/Combination Products 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development 30
Adamis Pharmaceuticals Corporation 30
Argos Therapeutics, Inc. 31
Asterias Biotherapeutics, Inc. 32
e-Therapeutics Plc 33
F. Hoffmann-La Roche Ltd. 34
Inovio Pharmaceuticals, Inc. 35
Invectys SA 36
Johnson & Johnson 37
Komipharm International Co., Ltd. 38
Mediolanum farmaceutici S.p.A. 39
Ultimovacs AS 40
Vaxon Biotech 41
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles 42
AGS-499 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ASTVAC-1 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ASTVAC-2 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ETS-2300 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Gene Therapy to Activate Telomerase for Alzheimer's Disease - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Gene Therapy to Activate Telomerase for Alzheimers Disease and Atherosclerosis - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
GX-301 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
imetelstat sodium - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
INO-1400 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
INO-5400 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
INVAC-1 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
KML-001 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
rocapuldencel-T - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Small Molecule to Target Telomerase for Lung Cancer - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Telin - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
TeloB-VAX - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
tertomotide - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
UCPVax - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
UV-1 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Vaccine to Target Telomerase for Oncology - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Vaccine to Target Telomerase Reverse Transcriptase for Solid Tumor - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Vbx-016 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Vbx-026 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Vx-001 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Vx-006 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Projects 85
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products 89
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Featured News & Press Releases 92
Sep 12, 2016: Geron Provides Update on Imetelstat Trials Being Conducted by Janssen 92
Jul 13, 2016: Geron Announces Issuance of U.S. Patents Related to Imetelstat 93
Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review 94
May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting 94
Apr 20, 2016: Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting 95
Mar 23, 2016: Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy 97
Mar 02, 2016: New trial launched to test cancer vaccine 97
Feb 24, 2016: Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1 99
Jan 21, 2016: Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial 100
Jan 14, 2016: Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes 101
Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis 102
Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting 102
Nov 05, 2015: Janssen to Present Posters on Imetelstat at the 2015 American Society of Hematology Annual Meeting 103
Oct 30, 2015: Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine 104
Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis 104
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107

List of Tables
Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Products under Investigation by Universities/Institutes, H2 2016 22
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 30
Pipeline by Argos Therapeutics, Inc., H2 2016 31
Pipeline by Asterias Biotherapeutics, Inc., H2 2016 32
Pipeline by e-Therapeutics Plc, H2 2016 33
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34
Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 35
Pipeline by Invectys SA, H2 2016 36
Pipeline by Johnson & Johnson, H2 2016 37
Pipeline by Komipharm International Co., Ltd., H2 2016 38
Pipeline by Mediolanum farmaceutici S.p.A., H2 2016 39
Pipeline by Ultimovacs AS, H2 2016 40
Pipeline by Vaxon Biotech, H2 2016 41
Dormant Projects, H2 2016 85
Dormant Projects (Contd..1), H2 2016 86
Dormant Projects (Contd..2), H2 2016 87
Dormant Projects (Contd..3), H2 2016 88
Discontinued Products, H2 2016 89
Discontinued Products (Contd..1), H2 2016 90
Discontinued Products (Contd..2), H2 2016 91

List of Figures
Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Top 10 Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 23
Number of Products by Mechanism of Actions, H2 2016 24
Number of Products by Stage and Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *